February 25

ADHD Drugs Addictive_NIDA study

For years leading child psychiatrists and the National Institute of Mental Health refused to entertain evidence of stimulant drug abuse and evidence suggesting that psychostimulant drugs–such as Ritalin– were addictive.  They ignored the long-term follow-up study by Dr. Nadine Lambert of California; they ignored the warnings by Dr. Peter Breggin–marginalizing him as a parriah.   

But a new study by the National Institute of Drug Abuse  (NIDA) surveyed 67,000 households and found that 1.6 million teenagers and young adults had misused stimulants, and that 75,000 "showed signs of addiction."
 
Recent revelations about these drugs’ toxic effects–recently the subject of an FDA advisory committee meeting–lead one to seriously wonder:
How trustworthy is the advice of child psychiatrists, and psychiatry’s leadership who have falsely reassured parents about the safety of these drugs?
Who bears greater responsibility–a street pusher of amphetamine or a licensed doctor who prescribes the same addictive drugs for children to modify their behavior?

Which is worse, the addicitive qualities or these drugs, or their toxic effects on the liver and cardiovascular system?
You be the judge.

Dr. Nora Volkow, head of NIDA said bluntly: "You are playing roulette," she said. "If you get addicted, you will not only not get into Harvard, you will not finish high school."

AHRP calls upon the NIMH to immediately suspend the preschool ADHD treatment study (PATS) which is exposing toddlers to these addictive drugs!

Contact: Vera Hassner Sharav
veracare@ahrp.org

Washington Post
Millions Have Misused ADHD Stimulant Drugs, Study Says
By Shankar Vedantam
Saturday, February 25, 2006; A09

More than 7 million Americans are estimated to have misused stimulant drugs meant to treat attention-deficit hyperactivity disorder, and substantial numbers of teenagers and young adults appear to show signs of addiction, according to a comprehensive national analysis tracking such abuse.

The statistics are striking because many young people recreationally using these drugs are seeking to boost academic and professional performance, doctors say.

Although the drugs may allow people to stay awake longer and finish work faster, scientists who published a new study concluded that about 1.6 million teenagers and young adults had misused these stimulants during a 12-month period and that 75,000 showed signs of addiction.

The study published online this month in the journal Drug and Alcohol Dependence culled data from a 2002 national survey of about 67,000 households.

The data paint a concrete and sobering picture of what many experts have worried about for years, and present ethical and medical challenges for a country where mental performance is highly valued and where the number of prescriptions for these drugs has doubled every five years, said Nora Volkow, director of the National Institute on Drug Abuse.

"We live in a highly competitive society, and you want to get the top grades and you know your colleagues are taking stimulants and you feel pressured," she said. "Yes, you are going to study better in the middle of the night if you take one of these medications. The problem is a certain percentage of people become addicted to them, and some have toxic effects."

Volkow said it was impossible to disentangle the skyrocketing prescriptions of drugs for attention-deficit hyperactivity disorder from the risks of diversion and abuse.

"As a child, you have multiple friends who are being treated with stimulant medications," she said. "You get the sense that these are good. The message we are getting cannot be under-emphasized — it has become something routine."

Studies have shown that the drugs are highly effective, especially among children, and also that they reduce the risk of substance abuse among those correctly diagnosed with the psychiatric disorder, which is characterized by inattention and unruly behavior. Untreated ADHD has also been associated with conduct and academic problems.

At the same time, there have been growing concerns that the drugs are over-prescribed. A Food and Drug Administration panel earlier this month warned that the medications carried risks of rare, but serious, cardiovascular problems, and it recommended that the agency place serious "black box" warnings on the drugs, as a way to restrain spiraling prescriptions.

Lawrence Diller, a pediatrician in Walnut Creek, Calif., who prescribes the drugs but is worried about their overuse, said that the new study showed the real health concerns are with diversion and abuse, not with rare side effects. "Seventy-five thousand addicts to prescription stimulants is much more troublesome than the 100 to 200 adults who have strokes," he said. "Houston, we have got a problem because we are just in the middle of this epidemic."

The study found that both men and women were equally likely to be misusing the drugs, but that women seemed to be at greater risk of dependence — characterized by a lack of control, physical need and growing tolerance for the drug — while men seemed to be at greater risk of abuse, in which the medication was used in dangerous situations, said lead author Larry Kroutil, who studies health behavior and education at RTI International, a nonprofit research group.

To obtain their findings, Kroutil and a team of researchers culled data from a 2002 national survey conducted by the federal government’s Substance Abuse and Mental Health Services Administration (SAMHSA). H. Westley Clark, director of SAMHSA’s Center for Substance Abuse Treatment, said the 2002 data were obtained through face-to-face interviews. RTI has not yet culled data from subsequent years regarding the misuse of ADHD drugs.

Since then, prescription rates and the popularity of various drugs have changed, and Kroutil said continuing research is needed to track the phenomenon. Clark noted that data from 2003 suggested that the problem of stimulant misuse was greater among young adults 18 to 25 years old than among teenagers.

The RTI study was paid for by Eli Lilly and Co., which makes the non-stimulant ADHD drug Strattera. Although non-stimulant treatments such as Strattera were an option for ADHD patients, they were often not as potent as stimulant drugs, Volkow said.

Both Volkow and Scott Kollins, who heads Duke University’s ADHD program, said the full range of ADHD drugs is a valuable tool. But Kollins said the study brought home what he has seen anecdotally: A colleague who visited his college-age son’s fraternity was mobbed by requests for Adderall prescriptions by youngsters seeking to boost academic performance.

"If I took Ritalin, I would probably stay up longer and write my grants faster," Kollins said. But besides the fact that he did not think this is right, Kollins said the rare side effects highlighted by the FDA panel meant people using the drugs for nonmedical purposes were placing themselves at risk for those adverse events.

Volkow was more blunt: "You are playing roulette," she said. "If you get addicted, you will not only not get into Harvard, you will not finish high school."

© 2006 The Washington Post Company

FAIR USE NOTICE: This may contain copyrighted (© ) material the use of which has not always been specifically authorized by the copyright owner. Such material is made available for educational purposes, to advance understanding of human rights, democracy, scientific, moral, ethical, and social justice issues, etc. It is believed that this constitutes a ‘fair use’ of any such copyrighted material as provided for in Title 17 U.S.C. section 107 of the US Copyright Law. This material is distributed without profit.


Subscribe To Our Newsletter!

Sign up and be the first to find out the latest news and articles about what's going on in the medical field.


You may also like

November 21, 2023

Vera Sharav is joining Christine Anderson as special guest for the Make It Your Business event in

Read More
Vera Sharav Joins Christine Anderson for Make It Your Business – Dec 4, 2023 in New Jersey

November 21, 2023

Vera Sharav is premiering the movie Never Again is Now Global in New York City, December 1.

Read More
Never Again is Now Global – Premiere Screening – Dec 1, 2023 in New York City